Corresponding Author: James B. Cutrell, MD, Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9113 (james.cutrell@utsouthwestern.edu).
Accepted for Publication: April 3, 2020.
Published Online: April 13, 2020. doi:10.1001/jama.2020.6019
Author Contributions: Dr Cutrell had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: Monogue, Jodlowski, Cutrell.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: Monogue, Jodlowski, Cutrell.
Administrative, technical, or material support: Cutrell.
Supervision: Cutrell.
Conflict of Interest Disclosures: Dr Cutrell reported receiving nonfinancial support from Regeneron and Gilead outside the submitted work. No other disclosures were reported.
Additional Contributions: We acknowledge our infectious disease physician and pharmacy colleagues at UT Southwestern and its respective hospital sites, Clements University Hospital, Parkland Hospital, and the VA North Texas Health Care System for their thoughtful discussions regarding COVID-19 clinical management.
3.Hoffmann
M , Kleine-Weber
H , Schroeder
S ,
et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
Cell. Published online March 4, 2020. doi:
10.1016/j.cell.2020.02.052
PubMedGoogle Scholar 8.Al-Bari
MAA . Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.
Pharmacol Res Perspect. 2017;5(1):e00293. doi:
10.1002/prp2.293
PubMedGoogle Scholar 9.Zhou
D , Dai
SM , Tong
Q . COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. [published online March 20, 2020].
J Antimicrob Chemother. 2020;dkaa114. doi:
10.1093/jac/dkaa114
PubMedGoogle Scholar 15.Yao
X , Ye
F , Zhang
M ,
et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. Published online March 9, 2020. doi:
10.1093/cid/ciaa237
PubMedGoogle Scholar 16.Gautret
P , Lagier
JC , Parola
P ,
et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. Published online March 20, 2020. doi:
10.1016/j.ijantimicag.2020.105949
PubMedGoogle Scholar 17.Chen
J , Liu
D , Liu
L ,
et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19).
J Zhejiang Univ (Med Sci). Published online March 6, 2020. doi:
10.3785/j.issn.1008-9292.2020.03.03Google Scholar 20.Lim
HS , Im
JS , Cho
JY ,
et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.
Antimicrob Agents Chemother. 2009;53(4):1468-1475. doi:
10.1128/AAC.00339-08
PubMedGoogle ScholarCrossref 22.de Wilde
AH , Jochmans
D , Posthuma
CC ,
et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.
Antimicrob Agents Chemother. 2014;58(8):4875-4884. doi:
10.1128/AAC.03011-14
PubMedGoogle ScholarCrossref 28.Khamitov
RA , Loginova
SIa , Shchukina
VN , Borisevich
SV , Maksimov
VA , Shuster
AM . Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures [in Russian].
Vopr Virusol. 2008;53(4):9-13.
PubMedGoogle Scholar 29.Wang
Z , Yang
B , Li
Q , Wen
L , Zhang
R . Clinical Features of 69 cases with coronavirus disease 2019 in Wuhan, China.
Clin Infect Dis. Published online March 16, 2020. doi:
10.1093/cid/ciaa272
PubMedGoogle Scholar 30.Siegel
D , Hui
HC , Doerffler
E ,
et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses.
J Med Chem. 2017;60(5):1648-1661. doi:
10.1021/acs.jmedchem.6b01594
PubMedGoogle ScholarCrossref 34.Avigan (favipiravir) [package insert]. Tokyo, Japan: Taisho Toyama Pharmaceutical Co Ltd; 2017, 4th version. Accessed March 25, 2020.
35.Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab.
chinaXiv. Preprint posted March 5, 2020. doi:
10.12074/202003.00026 38.Morra
ME , Van Thanh
L , Kamel
MG ,
et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis.
Rev Med Virol. 2018;28(3):e1977. doi:
10.1002/rmv.1977
PubMedGoogle Scholar 45.Yao
TT , Qian
JD , Zhu
WY , Wang
Y , Wang
GQ . A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. [published online February 27, 2020].
J Med Virol. 2020. doi:
10.1002/jmv.25729
PubMedGoogle Scholar 46.Chan
KS , Lai
ST , Chu
CM ,
et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.
Hong Kong Med J. 2003;9(6):399-406.
PubMedGoogle Scholar 47.Wu
C , Chen
X , Cai
Y ,
et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.
JAMA Intern Med. Published online March 13, 2020.
PubMedGoogle Scholar 48.Foolad
F , Aitken
SL , Shigle
TL ,
et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients.
Clin Infect Dis. 2019;68(10):1641-1649. doi:
10.1093/cid/ciy760
PubMedGoogle ScholarCrossref 49.Arabi
YM , Shalhoub
S , Mandourah
Y ,
et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study.
Clin Infect Dis. Published online June 25, 2019. doi:
10.1093/cid/ciz544
PubMedGoogle Scholar 51.Wang
D , Hu
B , Hu
C ,
et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
JAMA. Published online February 7, 2020. doi:
10.1001/jama.2020.1585
PubMedGoogle Scholar 54.Coleman
CM , Sisk
JM , Mingo
RM , Nelson
EA , White
JM , Frieman
MB . Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion.
J Virol. 2016;90(19):8924-8933. doi:
10.1128/JVI.01429-16
PubMedGoogle ScholarCrossref 55.Dyall
J , Gross
R , Kindrachuk
J ,
et al. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies.
Drugs. 2017;77(18):1935-1966. doi:
10.1007/s40265-017-0830-1
PubMedGoogle ScholarCrossref 66.Kujawski
SA , Wong
K , Collins
JP ,
et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States.
medRxiv. Preprint posted March 9, 2020. doi:
10.1101/2020.03.09.20032896 69.Sissoko
D , Laouenan
C , Folkesson
E ,
et al; JIKI Study Group. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea [published correction appears in
PLoS Med. 2016;13(4):e1002009].
PLoS Med. 2016;13(3):e1001967. doi:
10.1371/journal.pmed.1001967
PubMedGoogle Scholar 71.Chinello
P , Petrosillo
N , Pittalis
S , Biava
G , Ippolito
G , Nicastri
E ; INMI Ebola Team. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.
PLoS Negl Trop Dis. 2017;11(12):e0006034. doi:
10.1371/journal.pntd.0006034
PubMedGoogle Scholar 72.Kumagai
Y , Murakawa
Y , Hasunuma
T ,
et al. Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults.
Int J Clin Pharmacol Ther. 2015;53(10):866-874. doi:
10.5414/CP202388
PubMedGoogle ScholarCrossref 73.Chen
C , Huang
J , Cheng
Z ,
et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial.
medRxiv. Preprint posted March 27, 2020. doi:
10.1101/2020.03.17.20037432 75.Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing.
bioRxiv. Preprint posted March 22, 2020. doi:
10.1101/2020.03.22.002386 77.Arabi
YM , Mandourah
Y , Al-Hameed
F ,
et al; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome.
Am J Respir Crit Care Med. 2018;197(6):757-767. doi:
10.1164/rccm.201706-1172OC
PubMedGoogle ScholarCrossref 84.Arabi
Y , Balkhy
H , Hajeer
AH ,
et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.
Springerplus. 2015;4:709. doi:
10.1186/s40064-015-1490-9
PubMedGoogle ScholarCrossref 85.Hung
IF , To
KK , Lee
CK ,
et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.
Clin Infect Dis. 2011;52(4):447-456. doi:
10.1093/cid/ciq106
PubMedGoogle ScholarCrossref 86.Mair-Jenkins
J , Saavedra-Campos
M , Baillie
JK ,
et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.
J Infect Dis. 2015;211(1):80-90. doi:
10.1093/infdis/jiu396
PubMedGoogle ScholarCrossref 88.Cao
W , Liu
X , Bai
T ,
et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019.
Open Forum Infect Dis. Published online March 21, 2020. doi:
10.1093/ofid/ofaa102
Google Scholar 90.Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection.
bioRxiv. Preprint posted March 11, 2020. doi:
10.1101/2020.03.11.987958.2020 93.Yang
X , Yu
Y , Xu
J ,
et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Lancet Respir Med. Published online February 24, 2020. doi:
10.1016/S2213-2600(20)30079-5
PubMedGoogle Scholar 94.Young
BE , Ong
SWX , Kalimuddin
S ,
et al; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore.
JAMA. Published online March 3, 2020. doi:
10.1001/jama.2020.3204
PubMedGoogle Scholar 95.Guan
WJ , Ni
ZY , Hu
Y ,
et al; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med. Published online February 28, 2020. doi:
10.1056/NEJMoa2002032
PubMedGoogle Scholar